A transformative drug discovery platform for allosteric kinase inhibitors
变构激酶抑制剂的变革性药物发现平台
基本信息
- 批准号:10595089
- 负责人:
- 金额:$ 57.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-03-01 至 2026-02-28
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAdoptionAffinityBasic ScienceBindingBiochemicalBiological AssayBiophysicsBiosensorCancer PatientCancer cell lineChemicalsClassificationClinicalComplexCouplesDetectionDevelopmentDiseaseDissociationExonsFDA approvedFluorescenceFluorescence Resonance Energy TransferIndustrializationKnowledgeLibrariesLigandsMET geneMalignant NeoplasmsMalignant neoplasm of lungMediatingMinnesotaMissionMolecular ConformationMonitorMovementMutationOncologyOncoproteinsPatientsPhosphotransferasesProto-Oncogene Proteins c-mycReaderReceptor Protein-Tyrosine KinasesRegulatory ElementResearchResistanceResistance developmentSiteTechnologyTestingTherapeuticTranslatingUbiquitinationUniversitiesValidationc-myc Genescrizotinibdrug developmentdrug discoveryfield studyfollow-uphigh throughput screeningindustry partnerinhibitorinnovationinstrumentationkinase inhibitornanosecondnext generationnovelnovel strategiesnovel therapeutic interventionnovel therapeuticsphotonicspreventprogramsresistance mutationscaffoldsensorsensor technologysmall moleculesuccesstechnology developmenttherapeutic targettreatment strategytumortumorigenesis
项目摘要
Project Summary
The University of Minnesota (UMN) and Photonic Pharma (PP) a Minnesota-based drug discovery start-up, have
partnered to optimize, field-test, and deploy at industrial scale, an innovative new approach to developing
allosteric kinase inhibitors (AKI). These molecules have high potential as novel cancer therapeutics that
circumvent clinical resistance to conventional orthosteric kinase inhibitors (OKI). We have developed high-
throughput screening (HTS) technology based on nanosecond fluorescence lifetime (FLT) detection of Förster
resonance energy transfer (FRET), that tracks ligand-driven kinase allostery with angstrom precision by
monitoring structural changes of the activation loop, the key regulatory element in all kinases. This is the first
HTS-amenable technology that accurately resolves allosteric effects of kinase inhibitors, relying on high-quality
nanosecond FLT readouts unavailable from conventional fluorescence plate readers (PR). PP have developed
a proprietary HTS platform that uses FRET biosensors and a state-of-the-art FLT-PR to detect structural
readouts in <2 min for 384-well and <5 min for 1536-well plates. By partnering with PP, we will transform our
kinase FRET sensor technology into a broadly applicable drug-discovery platform for identifying AKIs.
We propose drug-discovery programs on two different targets to demonstrate broad utility and accelerate large-
scale adoption of our technology for drug development. In AIM 1, we identify Aurora A inhibitors that
downregulate the undruggable c-Myc oncoprotein by inhibiting the scaffolding interaction of Aurora A with c-
Myc. These molecules would represent a novel treatment strategy for the large number of cancer patients with
c-Myc-driven tumors. In AIM 2, we identify allosteric inhibitors of the c-MET receptor tyrosine kinase as a novel
therapeutic strategy for patients with c-MET-driven lung cancer. These patients invariably develop resistance to
current MET inhibitors through acquired mutations in the ATP site, and allosteric inhibitors that bind outside the
ATP-site would circumvent this mode of resistance, filling an unmet clinical need. This UMN-PP partnership
translates decades of biophysics research by two world-leading experts – Levinson and Thomas – toward drug-
discovery by resolving ligand-driven allostery in kinases. This is enabled by the FLT-PR instrumentation and
know-how required to implement nanosecond FLT detection in assays that resolve allosteric inhibitors in true
HTS mode. This overcomes key drawbacks of conventional kinase inhibitor screens, which detect kinase
inhibition or binding without regard to allosteric mechanism. The platform is broadly applicable, as almost all
kinases undergo the large-scale allosteric structural changes our technology detects. Success of this
project will catalyze adoption of this technology targeting a wide range of biomedically important kinases, as
highlighted by Photonic Pharma’s successful partnership with Bristol-Myers Squibb on drug discovery for other
high-priority therapeutic targets.
项目概要
明尼苏达大学 (UMN) 和 Photonic Pharma (PP) 是一家位于明尼苏达州的药物发现初创公司,
合作优化、现场测试和工业规模部署,这是一种创新的开发方法
变构激酶抑制剂(AKI)。这些分子具有作为新型癌症疗法的巨大潜力
规避对传统正构激酶抑制剂(OKI)的临床耐药性。我们开发了高
Förster 基于纳秒荧光寿命 (FLT) 检测的通量筛选 (HTS) 技术
共振能量转移(FRET),通过埃的精度追踪配体驱动的激酶变构
监测激活环的结构变化,激活环是所有激酶的关键调节元件。这是第一个
适合 HTS 的技术,依靠高质量准确解决激酶抑制剂的变构效应
传统荧光读板器 (PR) 无法提供纳秒级 FLT 读数。 PP已经开发出来
专有的 HTS 平台,使用 FRET 生物传感器和最先进的 FLT-PR 来检测结构
384 孔板可在 2 分钟内读出读数,1536 孔板可在 5 分钟内读出读数。通过与 PP 合作,我们将改变我们的
激酶 FRET 传感器技术成为广泛适用的药物发现平台,用于识别 AKI。
我们提出针对两个不同目标的药物发现计划,以展示广泛的效用并加速大规模应用
大规模采用我们的药物开发技术。在 AIM 1 中,我们鉴定出 Aurora A 抑制剂
通过抑制 Aurora A 与 c- 的支架相互作用来下调不可成药的 c-Myc 癌蛋白
米克。这些分子将为大量癌症患者提供一种新的治疗策略
c-Myc 驱动的肿瘤。在 AIM 2 中,我们将 c-MET 受体酪氨酸激酶的变构抑制剂确定为一种新型药物
c-MET 驱动的肺癌患者的治疗策略。这些患者总是会产生耐药性
目前的 MET 抑制剂通过 ATP 位点的获得性突变,以及结合在 ATP 位点外部的变构抑制剂
ATP 位点将规避这种耐药模式,满足未满足的临床需求。 UMN-PP 合作伙伴关系
将两位世界领先的专家莱文森和托马斯数十年的生物物理学研究转化为药物
通过解决激酶中配体驱动的变构来发现。这是通过 FLT-PR 仪器实现的
在真正解析变构抑制剂的测定中实施纳秒 FLT 检测所需的专业知识
高温超导模式。这克服了传统激酶抑制剂筛选的主要缺点,传统激酶抑制剂筛选检测激酶
抑制或结合,而不考虑变构机制。该平台适用范围广泛,几乎所有
激酶经历我们的技术检测到的大规模变构结构变化。此次成功
该项目将促进针对广泛的生物医学重要激酶的这项技术的采用,例如
Photonic Pharma 与百时美施贵宝在其他药物发现方面的成功合作伙伴关系凸显了这一点
高优先级的治疗目标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nicholas Mark Levinson其他文献
Nicholas Mark Levinson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nicholas Mark Levinson', 18)}}的其他基金
Targeting allosteric scaffolding functions of Aurora kinase A in cancer
靶向癌症中极光激酶 A 的变构支架功能
- 批准号:
10373096 - 财政年份:2021
- 资助金额:
$ 57.17万 - 项目类别:
A transformative drug discovery platform for allosteric kinase inhibitors
变构激酶抑制剂的变革性药物发现平台
- 批准号:
10097782 - 财政年份:2021
- 资助金额:
$ 57.17万 - 项目类别:
Targeting allosteric scaffolding functions of Aurora kinase A in cancer
靶向癌症中极光激酶 A 的变构支架功能
- 批准号:
10210065 - 财政年份:2021
- 资助金额:
$ 57.17万 - 项目类别:
Targeting allosteric scaffolding functions of Aurora kinase A in cancer
靶向癌症中极光激酶 A 的变构支架功能
- 批准号:
10593935 - 财政年份:2021
- 资助金额:
$ 57.17万 - 项目类别:
A transformative drug discovery platform for allosteric kinase inhibitors
变构激酶抑制剂的变革性药物发现平台
- 批准号:
10360449 - 财政年份:2021
- 资助金额:
$ 57.17万 - 项目类别:
Time-resolved FRET-based allostery sensors for any protein kinase drug target
适用于任何蛋白激酶药物靶标的时间分辨 FRET 变构传感器
- 批准号:
9887709 - 财政年份:2020
- 资助金额:
$ 57.17万 - 项目类别:
Time-resolved FRET-based allostery sensors for any protein kinase drug target
适用于任何蛋白激酶药物靶标的时间分辨 FRET 变构传感器
- 批准号:
10348717 - 财政年份:2020
- 资助金额:
$ 57.17万 - 项目类别:
Decoding the dynamic mechanism of allosteric activation in the cyclin-dependent kinase Cdk2
解读细胞周期蛋白依赖性激酶 Cdk2 变构激活的动态机制
- 批准号:
10321568 - 财政年份:2018
- 资助金额:
$ 57.17万 - 项目类别:
Kinome-Wide Spectroscopic Study of Drug Binding Site Electrostatics
药物结合位点静电的全激酶组光谱研究
- 批准号:
8351780 - 财政年份:2012
- 资助金额:
$ 57.17万 - 项目类别:
Kinome-Wide Spectroscopic Study of Drug Binding Site Electrostatics
药物结合位点静电的全激酶组光谱研究
- 批准号:
8973668 - 财政年份:2012
- 资助金额:
$ 57.17万 - 项目类别:
相似海外基金
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
- 批准号:
10093543 - 财政年份:2024
- 资助金额:
$ 57.17万 - 项目类别:
Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
- 批准号:
24K16436 - 财政年份:2024
- 资助金额:
$ 57.17万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 57.17万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 57.17万 - 项目类别:
EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
- 批准号:
24K20973 - 财政年份:2024
- 资助金额:
$ 57.17万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 57.17万 - 项目类别:
EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
- 批准号:
10075502 - 财政年份:2023
- 资助金额:
$ 57.17万 - 项目类别:
Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
- 批准号:
10089082 - 财政年份:2023
- 资助金额:
$ 57.17万 - 项目类别:
EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 57.17万 - 项目类别:
Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
- 批准号:
2321091 - 财政年份:2023
- 资助金额:
$ 57.17万 - 项目类别:
Standard Grant














{{item.name}}会员




